Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs Enveric Biosciences Inc (ENVB) Price & Performance

Dow Jones Industrial Average ETFTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs Enveric Biosciences Inc — how do they compare? Dow Jones Industrial Average ETF trades at $525.26, while Enveric Biosciences Inc trades at $1.28 (market cap $5.32M). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

DIAENVB
52-Week High
$530.02$17.40
52-Week Low
$435.72$1.28
Market Cap
$5.32M
Sector
Health
Enterprise Value
$408.82K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $524.40, down 0.27% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Dow Jones Industrial Average's 30 blue-chip stocks, providing diversified exposure to large-cap U.S. equities. Recent news highlights its 52-week high achievement and inclusion of Alphabet, boosting its tech weighting. Dividend distributions continue with scheduled payouts through mid-2026.

Outlook remains positive given the Dow's 8% year-to-date gain and DIA's 10-year average annual return of 13.3%. Key opportunities include broad market exposure and dividend income, while risks involve Fed policy shifts and concentration in cyclical sectors. Analyst sentiment is favorable due to the ETF's low-cost structure and historical performance.

Enveric Biosciences Inc

ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.

While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.

Returns comparison

Trailing returns across standard periods

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB